{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:06:41Z","timestamp":1783897601997,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","award":["Ionis Pharmaceuticals"],"award-info":[{"award-number":["Ionis Pharmaceuticals"]}],"id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-term prophylaxis (LTP) may reduce the hereditary angioedema (HAE) burden by reducing attack frequency, but real-world evidence is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe LTP treatment patterns and the frequency of HAE attacks leading to emergency department or inpatient visits (ED\/IP) and healthcare resource use (HRU) before and after LTP initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients initiating LTP in the Komodo Research Database (1\/1\/2021-1\/30\/2024) were followed until discontinuation or data end. Treatment adherence overall and among patients with &gt;\u200930 days of treatment was measured as the proportion of days covered\u2009\u2265\u200980%. Treatment persistence, defined as no interruption\u2009\u2265\u200990 days or switch, was evaluated overall and among patients with &gt;\u200930 days of treatment using Kaplan-Meier (KM) analysis with KM rates and corresponding 95% confidence intervals (CI). Rates of HAE attacks leading to ED\/IP and per-patient-per-year all-cause HRU before and after LTP initiation were reported among patients with &gt;\u200930 days of treatment. All analyses were descriptive and no statistical testing was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 499 patients were included (57 Haegarda [11%], 257 Orladeyo [52%], 185 Takhzyro [37%]; mean follow-up =\u200911.3 months; median age\u2009=\u200939 years; 69% female), among whom 449 had\u2009&gt;\u200930 days of treatment (mean follow-up =\u200912.5 months). At 12 months after LTP initiation, 52.6% of patients in the overall study sample and 57.0% of patients with &gt;\u200930 days of treatment were adherent. Based on KM analysis, persistence rates at 12 months after LTP initiation were 58.7% (95% CI\u2009=\u200953.8%; 63.4%) in the overall sample and 65.1% (59.9%; 69.9%) among patients with &gt;\u200930 days of treatment. Among the patients with &gt;\u200930 days of treatment, 38% had\u2009\u2265\u20091 HAE attack leading to ED\/IP in the year before LTP initiation (mean\u2009=\u20090.82 attacks), decreasing to 23% after (mean\u2009=\u20090.51 attacks). In these 449 patients, annual HRU remained substantial before and after LTP initiation across settings (IP\u2009=\u20092.4 and 1.7 days [0.3 and 0.2 admissions]; ED\u2009=\u20091.5 and 1.2 visits; outpatient\u2009=\u200921.0 and 19.3 visits, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although recently available LTP can partly reduce the clinical burden of patients with HAE, novel therapies are needed to further alleviate this burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04391-6","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:59:11Z","timestamp":1779191951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and clinical burden of patients with hereditary angioedema treated with long-term prophylaxis"],"prefix":"10.1186","volume":"21","author":[{"given":"William","family":"Lumry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Art","family":"Zbrozek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Thompson-Leduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Vera-Llonch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolaine","family":"Gauthier-Loiselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Vanden Eynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabelle","family":"Tardif-Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Radojicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"3","key":"4391_CR1","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","volume":"40","author":"ES Sinnathamby","year":"2023","unstructured":"Sinnathamby ES, Issa PP, Roberts L, Norwood H, Malone K, Vemulapalli H, et al. Hereditary angioedema: Diagnosis, clinical implications, and pathophysiology. Adv Ther. 2023;40(3):814\u201327.","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"4391_CR2","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2500\/aap.2020.41.200081","volume":"41","author":"Wedner","year":"2020","unstructured":"Wedner HJ. Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH). Allergy Asthma Proc. 2020;41(Suppl 1):S14\u20137.","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"4391_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.anai.2013.08.019","volume":"111","author":"A Banerji","year":"2013","unstructured":"Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329\u201336.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"4391_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.anai.2020.10.009","volume":"126","author":"MA Riedl","year":"2021","unstructured":"Riedl MA, Banerji A, Gower R. Current medical management of hereditary angioedema: follow-up survey of US physicians. Ann Allergy Asthma Immunol. 2021;126(3):264\u201372.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"4391_CR5","doi-asserted-by":"crossref","unstructured":"Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy & Asthma Proceedings. 2010;31(5).","DOI":"10.2500\/aap.2010.31.3394"},{"issue":"6","key":"4391_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.anai.2015.04.005","volume":"114","author":"N Javaud","year":"2015","unstructured":"Javaud N, Gompel A, Bouillet L, Boccon-Gibod I, Cantin D, Smaiti N, et al. Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. Ann Allergy Asthma Immunol. 2015;114(6):499\u2013503.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"4391_CR7","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.anai.2024.08.106","volume":"133","author":"E Kutrieb","year":"2024","unstructured":"Kutrieb E, Weycker D, Llonch MV, Zbrozek A, Harris AC, Ottino K, et al. Drug patterns, clinical outcomes, and economic costs among hereditary angioedema patients initiating long-term prophylaxis. Ann Allergy Asthma Immunol. 2024;133(6):S26.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"4391_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","volume":"124","author":"A Banerji","year":"2020","unstructured":"Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"4391_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-024-03265-z","volume":"19","author":"X Guan","year":"2024","unstructured":"Guan X, Sheng Y, Liu S, He M, Chen T, Zhi Y. Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review. Orphanet J Rare Dis. 2024;19(1):256.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"4391_CR10","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1016\/j.jaip.2025.08.020","volume":"13","author":"H Farkas","year":"2025","unstructured":"Farkas H, Anderson J, Bouillet L, Caballero T, Cancian M, Craig T, et al. Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension. J Allergy Clin Immunol Pract. 2025;13(11):3094\u2013e31033095.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"4391_CR11","first-page":"CD013403","volume":"11","author":"N Beard","year":"2022","unstructured":"Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022;11(11):CD013403.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"4391_CR12","first-page":"577","volume":"24","author":"A Mullard","year":"2025","unstructured":"Mullard A. FDA approves first factor XIIa inhibitor, for hereditary angioedema. Nat Rev Drug Discov. 2025;24(8):577.","journal-title":"Nat Rev Drug Discov"},{"key":"4391_CR13","unstructured":"Ionis Pharmaceuticals. Inc. DAWNZERA\u2122 (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema. August 2025; https:\/\/ir.ionis.com\/news-releases\/news-release-details\/dawnzeratm-donidalorsen-approved-us-first-and-only-rna-targeted"},{"issue":"6","key":"4391_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"4391_CR15","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.bone.2006.01.150","volume":"38","author":"J-Y Reginster","year":"2006","unstructured":"Reginster J-Y, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;38(4):S2\u20136.","journal-title":"Bone"},{"key":"4391_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-0998-8","volume":"20","author":"R Cowan","year":"2019","unstructured":"Cowan R, Cohen JM, Rosenman E, Iyer R. Physician and patient preferences for dosing options in migraine prevention. J Headache Pain. 2019;20:1\u201310.","journal-title":"J Headache Pain"},{"key":"4391_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","volume":"15","author":"S Betschel","year":"2019","unstructured":"Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hebert J, Kanani A, et al. The International\/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol. 2019;15:72.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"12","key":"4391_CR18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","volume":"376","author":"H Longhurst","year":"2017","unstructured":"Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131\u201340.","journal-title":"N Engl J Med"},{"issue":"6","key":"4391_CR19","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.jaip.2021.03.057","volume":"9","author":"HJ Wedner","year":"2021","unstructured":"Wedner HJ, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Bernstein J, Craig T, Gower R, Jacobs JS, et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). J Allergy Clin Immunology: Pract. 2021;9(6):2305\u201314. e2304.","journal-title":"J Allergy Clin Immunology: Pract"},{"issue":"3","key":"4391_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/all.15011","volume":"77","author":"A Banerji","year":"2022","unstructured":"Banerji A, Bernstein JA, Johnston DT, Lumry WR, Magerl M, Maurer M, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy. 2022;77(3):979\u201390.","journal-title":"Allergy"},{"issue":"5","key":"4391_CR21","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.anai.2023.08.097","volume":"131","author":"W Lumry","year":"2023","unstructured":"Lumry W, Davis-Lorton M, Soteres D, Earl L, Wynne-Cattanach K, Sing K, et al. Real-world outcomes in patients with HAE receiving lanadelumab long-term prophylaxis for 3 years or longer. Ann Allergy Asthma Immunol. 2023;131(5):S29.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"4391_CR22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.18553\/jmcp.2025.31.6.578","volume":"31","author":"SC Christiansen","year":"2025","unstructured":"Christiansen SC, Lopez-Gonzalez L, MacKnight SD, Lalibert\u00e9 F, Spencer C, Boudreau J, et al. Reductions in medical visits and hospitalizations following berotralstat initiation in patients with hereditary angioedema in the United States. J Managed Care Specialty Pharm. 2025;31(6):578\u201389.","journal-title":"J Managed Care Specialty Pharm"},{"issue":"5","key":"4391_CR23","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.anai.2023.08.127","volume":"131","author":"M Davis-Lorton","year":"2023","unstructured":"Davis-Lorton M, Soteres D, Lumry W, Hall J, Connolly H, Fox D, et al. Real-world quality of life in patients with HAE receiving lanadelumab or other long-term prophylaxis. Ann Allergy Asthma Immunol. 2023;131(5):S40.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"4391_CR24","doi-asserted-by":"publisher","first-page":"AB135","DOI":"10.1016\/j.jaci.2022.12.421","volume":"151","author":"K Park","year":"2023","unstructured":"Park K, Yeich A, Craig T. Evaluating the impact of acute versus prophylaxis therapy in hereditary angioedema. J Allergy Clin Immunol. 2023;151(2):AB135.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04391-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04391-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04391-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:47:17Z","timestamp":1783896437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04391-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4391"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04391-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was considered exempt research under 45 CFR \u00a7\u00a046.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR \u00a7\u00a0164.514. Therefore, no Institutional Review Board or Ethics Committee approval was sought for the conduct of the study. Since only de-identified data were used for the study, patient consent to participate was not sought.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MV-L is an employee and stockholder of Ionis Pharmaceuticals. AZ is an employee of BioPoint Pharmaceutical and Biotech Consulting working for Ionis Pharmaceuticals. PT-L, MGL, CVE, ATS, and AG are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Ionis Pharmaceuticals, which funded the development and conduct of this study and manuscript. WL declares consultant arrangements with Astria, BioCryst, Biomarin, CSL Behring, Express Scripts\/CVS, Intellia, Kalvista, Magellan, Optum, Pharming, Pharvaris, Shire\/Takeda; speakers\u2019 bureau from BioCryst, CSL Behring, Kalvista, Pharming, Shire\/Takeda, Grifols, Astra Zeneca and Regeneron; current grants\/research support from AstraZeneca, Astria, BioMarin, CSL Behring, Grifols, Intellia, Ionis, Kalvista, Lilly, Novartis, Pharvaris, Shire\/Takeda, Teva, Up Stream Bio, and board membership at the US Hereditary Angioedema Association Medical Advisory Board, and DFW Metroplex Allergy Society. CR has received consultancy fees from CSL Behring, Kalvista Pharmaceuticals, Ionis Pharmaceuticals, Intellia Therapeutics, Pharvaris, Biocryst Pharmaceuticals, and was on the speaker\u2019s bureau for CSL Behring, Ionis Pharmaceuticals and Kalvista Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"247"}}